aDivision of Rheumatology, Department of Medicine

bUniversity of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA

cTameside Hospital, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne

dDivision of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK

Correspondence to Michael Hughes, BSc (Hons), MBBS, MSc, MRCP, (UK) (Rheumatology) PhD, Consultant Rheumatologist, Department of Rheumatology, Tameside Hospital, Tameside and Glossop Integrated NHS Foundation Trust, Ashton-under-Lyne, UK. Tel: +44 114 271 1900; e-mail: [email protected]